I am an individual investor who has been operating strictly in the biotech sector over the last five years. I currently do not engage in any options trading but expect that will change as I become more experienced and comfortable with the concepts and strategies. I am frequently on Twitter: @kevinccc
I am a Master of the arts but am involved in many types of investing and trading. My areas of research are primarily biotechnology and disruptive technology. I am interested in turnaround, contrarian, trend following, and (deep) value situations.
I am developing proprietary, quantitative investment strategies; and I operate a website for investors and others.
Adam Gefvert is the head researcher for White Diamond Research, a research firm for hedge funds and high net worth individuals. You can read those reports at whitediamondresearch.com.
Primarily a short seller, he has saved investors millions of dollars by exposing highly overvalued small cap stocks. He has a 90%+ success rate with his Seeking Alpha short ideas. He specializes in technology, energy, and biotech stocks, because those are the sectors with the greatest valuation inefficiencies. You can follow Adam on twitter @shiningboy
Have been an investor for 60 years. Last 20 years have concentrated on biotechs. Have been senior exec with Shell and ITT before retiring 30+ years ago. My working areas were finance, informatics and international management. Taught MBA courses in management, informatics and communications. Speak French and Spanish plus some German.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
81 years old and counting.
PhD in Biochem, minor Genetics, UNC Chapel Hill.
MS Analytical Chem, St. Joseph's. (evening college).
BSc Chem, PCPS, now USP Philadelphia.
Hobby: Neurophysiological basis of the Rise and Fall of Civilizations
More-or-less self-taught individual small investor, who started late.
IMHO, Seeking Alpha is THE PREMIUM SITE w/o a peer!
I am an analyst at an Alternative Investment Manager and Commodity Trading Advisor located in Northern New Jersey.
I previously have worked at Societe Generale on the Securities Lending Trading Desk and at Merrill Lynch in the Credit Derivatives Department.
I graduated from Northeastern University in Boston, MA with a dual degree in Finance and Accounting and was a member of the Honors Program.
I currently invest in biotech stocks, mostly well ahead of ADCOM and PDUFA catalysts. I enjoy the satisfaction of knowing my equity is involved in the research and development of potential life-saving and life-improving technologies and medicines.